Scholar Rock Holding, a biotech targeting growth factor inhibition for spinal muscular atrophy, raised $75 million by offering 5.36 million shares at $14, within the range of $13 to $15. At that price, it commands a fully-diluted market value of $350 million.
...read more
Led by digital lending platform GreenSky and global merchant acquirer EVO Payments, eight companies are scheduled to raise a combined $1.3 billion in the week ahead. GreenSky and EVO are joined by three biotechs, a bioprosthetic device company and two small...read more
Scholar Rock Holding, a preclinical biotech targeting growth factor inhibition for a variety of diseases, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $75 million by offering 5.4 million shares at a price range of...read more
US IPO Weekly Recap: Payment IPOs pay off as 6 deals price ahead of Memorial Day
This week's highlights: 6 IPOs, including 3 biotechs and 2 payment firms, raised $1.4...read more
Growth factor biotech Scholar Rock prices $75 million IPO at $14 midpoint
Scholar Rock Holding, a biotech targeting growth factor inhibition for spinal muscular atrophy, raised $75 million by offering 5.36 million shares at $14, within the range of $13 to $15. At that price, it commands a fully-diluted market value of $350 million. ...read more
US IPO Week Ahead: GreenSky and EVO Payments lead 8-IPO week
Led by digital lending platform GreenSky and global merchant acquirer EVO Payments, eight companies are scheduled to raise a combined $1.3 billion in the week ahead. GreenSky and EVO are joined by three biotechs, a bioprosthetic device company and two small...read more
Growth factor biotech Scholar Rock sets terms for $75 million IPO
Scholar Rock Holding, a preclinical biotech targeting growth factor inhibition for a variety of diseases, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $75 million by offering 5.4 million shares at a price range of...read more